Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
Healthcare
$2.29 +0.67%
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
52W Low $1.10High $3.60
Volume 0.81M
Average 0.40M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$123.83M
FY 2025 · Annual
Net Income
-$121.33M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| 38.27M | 40.6M | 48.49M | 60.01M | 60.56M | |
| 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
ABOS Earnings Waterfall · TTM
NASDAQ:ABOS · Revenue to Net Income
Key Ratios
EPS$-1.87
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$113.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.87, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 16, 2026 | |
| S-8 | S-8 filing | Aug 12, 2026 | |
| 8-K | Current report | Aug 12, 2026 | |
| 10-Q | Quarterly report | Aug 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 17, 2026 |
How much revenue does ABOS generate?
Acumen Pharmaceuticals, Inc. (ABOS) reported $0.00 of revenue in fiscal 2025.
Is ABOS profitable?
Acumen Pharmaceuticals, Inc. (ABOS) reported -$121.33M of net income.
Continue the stock analysis
Jump to another research area for this company.